Detalhe da pesquisa
1.
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12.
Cancer Immunol Immunother
; 72(8): 2783-2797, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166485
2.
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Blood
; 122(7): 1293-304, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23836560
3.
Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach.
Transl Oncol
; 44: 101943, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593586
4.
Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence.
Front Oncol
; 14: 1376622, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38741774
5.
In-hospital cardiac arrests: effect of amended Australian Resuscitation Council 2006 guidelines.
Aust Health Rev
; 37(2): 178-84, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23575506
6.
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies.
J Immunother Cancer
; 10(12)2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564129
7.
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244306
8.
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
J Immunother Cancer
; 9(2)2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602696
9.
Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.
Cancer Res Commun
; 1(3): 127-139, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35765577
10.
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.
Cancer Immunol Res
; 9(2): 239-252, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355290
11.
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741731
12.
Overcoming hypoxia-induced functional suppression of NK cells.
J Immunother Cancer
; 8(1)2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32345623
13.
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
J Immunother Cancer
; 8(1)2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32439799
14.
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Elife
; 92020 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32633234
15.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Clin Cancer Res
; 26(16): 4268-4279, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32398324
16.
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
Oral Oncol
; 90: 38-44, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30846174
17.
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Oral Oncol
; 95: 127-135, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345380
18.
Correction to: Immunotherapy Utilizing the Combination of Natural Killer- and Antibody Dependent Cellular Cytotoxicity (ADCC)-Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition.
J Immunother Cancer
; 7(1): 234, 2019 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31477176
19.
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
JCI Insight
; 4(20)2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31536478
20.
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
J Immunother Cancer
; 6(1): 133, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30486888